Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients
ConclusionSpleen [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [68Ga]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities.
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Adenocarcinoma | Brain | Cancer | Cancer & Oncology | Desmoplastic Small Round Cell Tumor (DSRCT) | Laboratory Medicine | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | PET Scan | Radiology | Study